|
Phase 3, randomized, placebo-controlled trials evaluating glasdegib in combination with intensive or nonintensive chemotherapy in patients with untreated acute myeloid leukemia. |
|
|
Consulting or Advisory Role - Amphivena Therapeutics; Astellas Pharma; Bio-Path Holdings, Inc; BiolineRx; Bristol-Myers Squibb; Daiichi Sankyo; Novartis; Pfizer; Takeda |
Research Funding - Ambit BioSciences (Inst); Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Immunogen (Inst); Novartis (Inst); Pfizer (Inst); Sun Pharma (Inst); Takeda (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Agios; Pfizer |
Research Funding - Pfizer |
|
|
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Pfizer |
Research Funding - Novartis |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - GlaxoSmithKline; Novartis; Pfizer |
|
|
Consulting or Advisory Role - Celgene; Millennium |